Form 4 for PRLD Prelude Therapeutics Inc
Accepted 2021-12-15 00:00:00 ET · period of report 2021-12-13 · accession 0001209191-21-069796 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2021-12-15 | 2021-12-13+ | PRLD | Combs Andrew | EVP, Head of Chemistry | P - Purchase | $11.86 | +8,000 | 268.4K | +3% | +$94.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-12-13 | P | A | 4,000 | $12.12 | 264,380 | D | — | — | (F1) Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. |
| 2 | Common | Common Stock | 2021-12-14 | P | A | 4,000 | $11.60 | 268,380 | D | — | — | (F1) Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. |